Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL14915907

CCCCC(CC)Cc1nc(Nc2ccc(-c3nc4cc(C(C)(C)CC)ccc4o3)cc2)nc(Nc2ccc(-c3nc4cc(C(C)(C)CC)ccc4o3)cc2)n1.N

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.38
HSD17B10 Q99714 8/20 0.38
KDM4E B2RXH2 7/20 0.38
MAPT P10636 3/20 0.38
USP2 O75604 2/20 0.38
TSHR P16473 2/20 0.38
PTPN5 P54829 2/20 0.38
F2RL3 Q96RI0 1/20 0.38
HPGD P15428 7/20 0.37
RAB9A P51151 5/20 0.37
NPC1 O15118 4/20 0.37
GFER P55789 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
CASP3 P42574 4/20 0.36
SENP7 Q9BQF6 4/20 0.36
TP53 P04637 3/20 0.36
SENP8 Q96LD8 3/20 0.36
SENP6 Q9GZR1 3/20 0.36
HSPD1 P10809 1/20 0.35
PTPN2 P17706 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29724216 0.89 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL432261 0.89 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL23071375 0.85 RAB9A (0.39) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL21586960 0.83 MAPT (0.43) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL17576045 0.83 ALDH1A1 (0.43) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL6927621 0.82 RAB9A (0.43) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL25769745 0.81 NPC1 (0.46) ALDH1A1HSD17B10KDM4EMAPTPTPN5
SCHEMBL24068960 0.80 NPC1 (0.50) ALDH1A1HSD17B10KDM4EMAPTUSP2
SCHEMBL8079864 0.80 NPC1 (0.45) ALDH1A1HSD17B10KDM4EMAPTTSHR
SCHEMBL23021160 0.79 MAPT (0.41) ALDH1A1HSD17B10KDM4EMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016939-B2 Skin treatment methods and compositions for transdermal delivery of active agents TOPIX PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-20240108556-A1 SCAR TREATMENT COMPOSITION TOPIX PHARMACEUTICALS, INC. 2024-04-04 US disclosed
US-20240075112-A1 SCAR TREATMENT COMPOSITION TOPIX PHARMACEUTICALS, INC. 2024-03-07 US disclosed
US-20230190593-A1 SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS TOPIX PHARMACEUTICALS, INC. 2023-06-22 US disclosed
US-11596584-B2 Skin treatment methods and compositions for transdermal delivery of active agents TOPIX PHARMACEUTICALS, INC. (US) 2023-03-07 US disclosed
US-20210401682-A1 TOPICAL VITAMIN C COMPOSITION TOPIX PHARMACEUTICALS, INC. 2021-12-30 US disclosed
US-20210212908-A1 SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS TOPIX PHARMACEUTICALS, INC. 2021-07-15 US disclosed
US-9987211-B2 Sunless tanning compounds and compositions REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2018-06-05 US disclosed
US-20170000712-A1 SUNLESS TANNING COMPOUNDS AND COMPOSITIONS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2017-01-05 US disclosed
WO-2015003095-A1 SUNLESS TANNING COMPOUNDS AND COMPOSITIONS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2015-01-08 WO disclosed
US-8906351-B2 2,2′-furoin derivatives and use thereof to light skin MERCK PATENT GMBH (DE) 2014-12-09 US disclosed
US-20130272978-A1 DIHYDROXYACETONE MONOETHERS MERCK PATENT GMBH (DE) 2013-10-17 US disclosed
US-20130261175-A1 2-PYRONES MERCK PATENT GMBH (DE) 2013-10-03 US disclosed
US-20130164230-A1 2,2'-FUROIN DERIVATIVES AND USE THEREOF TO LIGHT SKIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-06-27 US disclosed
US-20130115178-A1 TANNING ENHANCERS AND SELF-TANNING SUBSTANCES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130164230-A1 2,2'-FUROIN DERIVATIVES AND USE THEREOF TO LIGHT SKIN TYR, ALDH1A2, MC1R ALDH1A1 63/4885HSD17B10 439/4885KDM4E 4348/4885
US-20170000712-A1 SUNLESS TANNING COMPOUNDS AND COMPOSITIONS TYR, SUN2, ERCC4 ALDH1A1 1404/4885HSD17B10 2192/4885KDM4E 2412/4885
US-20240108556-A1 SCAR TREATMENT COMPOSITION MMP1, MMP8, PLAT ALDH1A1 296/4885HSD17B10 462/4885KDM4E 2616/4885
US-20210401682-A1 TOPICAL VITAMIN C COMPOSITION TTPA, PROC, RBP4 ALDH1A1 963/4885HSD17B10 2143/4885KDM4E 3248/4885
US-20230190593-A1 SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS CUTA, MMP1, TYR ALDH1A1 2153/4885HSD17B10 2361/4885KDM4E 4392/4885
US-11596584-B2 Skin treatment methods and compositions for transdermal delivery of active agents CUTA, MMP1, TYR ALDH1A1 2153/4885HSD17B10 2361/4885KDM4E 4392/4885
US-20240075112-A1 SCAR TREATMENT COMPOSITION MMP1, MMP8, MMP2 ALDH1A1 173/4885HSD17B10 405/4885KDM4E 1907/4885
US-20130115178-A1 TANNING ENHANCERS AND SELF-TANNING SUBSTANCES DERA, ALDOA, GALE ALDH1A1 5/4885HSD17B10 127/4885KDM4E 980/4885
US-20130261175-A1 2-PYRONES PYCR1, CYP17A1, CYP11B2 ALDH1A1 658/4885HSD17B10 127/4885KDM4E 1753/4885
US-20130272978-A1 DIHYDROXYACETONE MONOETHERS GNPAT, UGT1A7, UGT1A3 ALDH1A1 27/4885HSD17B10 30/4885KDM4E 1761/4885
US-12016939-B2 Skin treatment methods and compositions for transdermal delivery of active agents CUTA, MMP1, TYR ALDH1A1 2153/4885HSD17B10 2361/4885KDM4E 4392/4885
US-20210212908-A1 SKIN TREATMENT METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS CUTA, MMP1, TYR ALDH1A1 2153/4885HSD17B10 2361/4885KDM4E 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.